PATENT CLAIM ANALYSIS

Application Number: 16159545
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-05
Patent Classification: ["424", "136100"]

Abstract:
Disclosed herein are B cell maturation antigen binding proteins with improved binding affinities and improved ability to mediate killing of cancer cells expressing B cell maturation antigen (BCMA). Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of treatment of a cancer or a metastasis thereof using such formulations are further provided.

Claim (Index 18):
The domain BCMA binding protein of  claim 1 , wherein said protein has an elimination half-time of at least 12 hours, at least 20 hours, at least 25 hours, at least 30 hours, at least 35 hours, at least 40 hours, at least 45 hours, at least 50 hours, or at least 100 hours.

Metadata:
- Claim Count in Document: 23.0
- Percentile: 97.0
- Lexical Diversity: 1.39024
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15977968', '15476309', '14805193', '15501620', '15237889']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7538400034834869
- 35 USC 102 Novelty (BERT): 0.5562305189202655
- Combined Prediction Score: 0.7340790550271648
- Mean Citation Score: 425.49164400000006
- Max Citation Score: 469.59668
- Similarity Product: 260.1009257198096

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test